Alnylam Pharmaceuticals

Alnylam leads the advancement of RNA interference (RNAi) into a completely new category of innovative drugs with the potential to revolutionize the lives of patients who have limited or inadequate treatment options. Based on the award-winning Nobel Prize science, RNAi therapeutics signify a potent, clinically proven approach for addressing a broad spectrum of debilitating diseases with significant unmet medical requirements. Alnylam is recognized for its robust exploration platform and extensive pipeline of experimental drugs, encompassing 4 programs in advanced clinical development.